+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Multi Cancer Early Detection Market Size, Share & Trends Analysis Report By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 125 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 5967385
Description Jump to:

Multi Cancer Early Detection Market Growth & Trends

The global multi cancer early detection market size is expected to reach USD 2.86 billion by 2030, registering a CAGR of 17% from 2025 to 2030. The need for providing effective ways to detect cancer at an early stage so that the right treatment can be given and the rising prevalence of cancer and multiple forms are expected to fuel the growth of the market. The requirement for early detection diagnostics, which facilitates simple disease management and subsequently lowers the death rate, drives the overall market.

Multi cancer early detection (MCED) tests are designed to find tumors in the body even when a patient is asymptomatic. To determine whether there is a high probability that a person has cancer, they simultaneously evaluate several signals. Although numerous tests are being developed to detect cancer at an early stage, the first MCED screening test was just recently made available in the U.S. as a lab-developed test. For instance, in July 2022, GRAIL’s Galleri was made available as an LDT at Mercy, St. Louis. Furthermore, MCED screening tests are being developed by Exact Sciences and Freenome, and GRAIL's Galleri test is being marketed without payer coverage with the claim that it can detect up to fifty different forms.

Studies show that MCED tests have a higher sensitivity for detecting later-stage or advanced than for detecting earlier stages, which are more treatable and occasionally curable. Additionally, it was found that the tests were highly specific, which made it extremely unlikely that they would give a positive result for someone who did not have cancer. To meet the demand for early diagnosis, ongoing research is still being done in the field of developing MCED.

The major players in the market assert that they can identify as few as two or three different cancer types or as many as fifty. They are focusing on the growth and development of these screening tests and faster commercialization. For instance, in December 2020, Singlera Genomics raised $150 million in Series B funding for the development, marketing, and promotion of its MCED tests. GRAIL launched a pilot project with Point32Health, making Point32Health the first commercial plan for health to include MCED tests.

Multi Cancer Early Detection Market Report Highlights

  • The gene panel, LDT, & others segment led the market and accounted for a share of 91.28% in 2024. The growth of the segment is attributed to the non-requirement of FDA approval for the utilization of LDT in diagnostic laboratories.
  • The liquid biopsy segment is anticipated to grow at the fastest CAGR over the forecast period. The growth of this segment is attributed to the increasing number of players receiving funding from investors for the development of new tests.
  • The hospitals end-use segment led the market with a share of 48.44% in 2024. This is attributed to the growing preference of hospitals for care due to the availability of various services under one roof.
  • Asia Pacific multi cancer early detection market is anticipated to witness the fastest CAGR over the forecast period due to a significantly improving healthcare infrastructure, a growing population, and a rising number of local companies entering the market

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Multi Cancer Early Detection (MCED) Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of cancer
3.2.1.2. Extensive R&D for the development of MCED
3.2.1.3. Need to develop diagnostic options that can detect cancer at an early stage
3.2.2. Market restraint analysis
3.2.2.1. Collection of adequate safety and efficacy data for regulatory approval
3.3. Multi Cancer Early Detection (MCED) Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Multi Cancer Early Detection (MCED) Market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Multi Cancer Early Detection (MCED) Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Liquid Biopsy
4.5.1. Liquid biopsy market estimates and forecasts 2018 - 2030 (USD Million)
4.6. Gene Panel, LDT, and Others
4.6.1. Gene panel, LDT, and others market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5. Multi Cancer Early Detection (MCED) Market: End Use Estimates & Trend Analysis
5.1. End Use Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Multi Cancer Early Detection (MCED) Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Hospitals
5.5.1. Hospitals market estimates and forecasts 2018 - 2030 (USD million)
5.6. Diagnostic Laboratories
5.6.1. Diagnostic laboratories market estimates and forecasts 2018 - 2030 (USD Million)
5.7. Other
5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6. Multi Cancer Early Detection (MCED) Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
6.8.2. Argentina
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2024
7.3.4. Illumina, Inc. (GRAIL, LLC)
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. GRAIL, Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Exact Sciences Corporation
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. FOUNDATION MEDICINE, INC.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. AnchorDx
7.3.8.1. Company overview
7.3.8.2. Product benchmarking
7.3.8.3. Strategic initiatives
7.3.9. Guardant Health
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Burning Rock Biotech Limited
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. GENECAST
7.3.11.1. Company overview
7.3.11.2. Product benchmarking
7.3.11.3. Strategic initiatives
7.3.12. Beijing Lyman Juntai International Medical Technology Development Co.
7.3.12.1. Company overview
7.3.12.2. Product benchmarking
7.3.12.3. Strategic initiatives
7.3.13. Freenome Holdings, Inc.
7.3.13.1. Company overview
7.3.13.2. Product benchmarking
7.3.13.3. Strategic initiatives
7.3.14. Elypta AB
7.3.14.1. Company overview
7.3.14.2. Product benchmarking
7.3.14.3. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
Table 3 North America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 4 North America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 5 U.S. multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 6 U.S. multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 7 Canada multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 8 Canada multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 9 Mexico multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 10 Mexico multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 11 Europe multi cancer early detection market, by region, 2018 - 2030 (USD Million)
Table 12 Europe multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 13 Europe multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 14 Germany multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 15 Germany multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 16 UK multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 17 UK multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 18 France multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 19 France multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 20 Italy multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 21 Italy multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 22 Spain multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 23 Spain multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 24 Denmark multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 25 Denmark multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 26 Sweden multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 27 Sweden multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 28 Norway multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 29 Norway multi cancer early detection market, by end use, 2018 - 2030 (USD Million)Asia Pacific multi cancer early detection market, by region, (USD Million) 2018 - 2030 (USD Million)
Table 30 Asia Pacific multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 31 China multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 32 China multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 33 Japan multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 34 Japan multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 35 India multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 36 India multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 37 South Korea multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 38 South Korea multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 39 Australia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 40 Australia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 41 Thailand multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 42 Thailand multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 43 Latin America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
Table 44 Latin America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 45 Latin America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 46 Brazil multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 47 Brazil multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 48 Argentina multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 49 Argentina multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 50 MEA multi cancer early detection market, by region, 2018 - 2030 (USD Million)
Table 51 MEA multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 52 MEA multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 53 South Africa multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 54 South Africa multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 55 Saudi Arabia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 56 Saudi Arabia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 57 UAE multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 58 UAE multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
Table 59 Kuwait multi cancer early detection market, by type, 2018 - 2030 (USD Million)
Table 60 Kuwait multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Multi cancer early detection market: market outlook
Fig. 14 Tumor ablation competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Multi cancer early detection market driver impact
Fig. 20 Multi cancer early detection market restraint impact
Fig. 21 Multi cancer early detection market strategic initiatives analysis
Fig. 22 Multi cancer early detection market: Type movement analysis
Fig. 23 Multi cancer early detection market: Type outlook and key takeaways
Fig. 24 Liquid biopsy market estimates and forecast, 2018 - 2030
Fig. 25 Gene panel, LDT, & others estimates and forecast, 2018 - 2030
Fig. 26 Multi cancer early detection market: End Use movement Analysis
Fig. 27 Multi cancer early detection market: End Use outlook and key takeaways
Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030
Fig. 29 Diagnostic laboratories market estimates and forecasts, 2018 - 2030
Fig. 30 Others market estimates and forecasts,2018 - 2030
Fig. 31 Global multi cancer early detection market: Regional movement analysis
Fig. 32 Global multi cancer early detection market: Regional outlook and key takeaways
Fig. 33 Global multi cancer early detection market share and leading players
Fig. 34 North America market share and leading players
Fig. 35 Europe market share and leading players
Fig. 36 Asia Pacific market share and leading players
Fig. 37 Latin America market share and leading players
Fig. 38 Middle East & Africa market share and leading players
Fig. 39 North America: SWOT
Fig. 40 Europe SWOT
Fig. 41 Asia Pacific SWOT
Fig. 42 Latin America SWOT
Fig. 43 MEA SWOT
Fig. 44 North America, by country
Fig. 45 North America
Fig. 46 North America market estimates and forecasts, 2018 - 2030
Fig. 47 U.S.
Fig. 48 U.S. market estimates and forecasts, 2018 - 2030
Fig. 49 Canada
Fig. 50 Canada market estimates and forecasts, 2018 - 2030
Fig. 51 Mexico
Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
Fig. 53 Europe
Fig. 54 Europe market estimates and forecasts, 2018 - 2030
Fig. 55 UK
Fig. 56 UK market estimates and forecasts, 2018 - 2030
Fig. 57 Germany
Fig. 58 Germany market estimates and forecasts, 2018 - 2030
Fig. 59 France
Fig. 60 France market estimates and forecasts, 2018 - 2030
Fig. 61 Italy
Fig. 62 Italy market estimates and forecasts, 2018 - 2030
Fig. 63 Spain
Fig. 64 Spain market estimates and forecasts, 2018 - 2030
Fig. 65 Denmark
Fig. 66 Denmark market estimates and forecasts, 2018 - 2030
Fig. 67 Sweden
Fig. 68 Sweden market estimates and forecasts, 2018 - 2030
Fig. 69 Norway
Fig. 70 Norway market estimates and forecasts, 2018 - 2030
Fig. 71 Asia Pacific
Fig. 72 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 73 China
Fig. 74 China market estimates and forecasts, 2018 - 2030
Fig. 75 Japan
Fig. 76 Japan market estimates and forecasts, 2018 - 2030
Fig. 77 India
Fig. 78 India market estimates and forecasts, 2018 - 2030
Fig. 79 Thailand
Fig. 80 Thailand market estimates and forecasts, 2018 - 2030
Fig. 81 South Korea
Fig. 82 South Korea market estimates and forecasts, 2018 - 2030
Fig. 83 Australia
Fig. 84 Australia market estimates and forecasts, 2018 - 2030
Fig. 85 Latin America
Fig. 86 Latin America market estimates and forecasts, 2018 - 2030
Fig. 87 Brazil
Fig. 88 Brazil market estimates and forecasts, 2018 - 2030
Fig. 89 Argentina
Fig. 90 Argentina market estimates and forecasts, 2018 - 2030
Fig. 91 Middle East and Africa
Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 93 South Africa
Fig. 94 South Africa market estimates and forecasts, 2018 - 2030
Fig. 95 Saudi Arabia
Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 97 UAE
Fig. 98 UAE market estimates and forecasts, 2018 - 2030
Fig. 99 Kuwait
Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 101 Market share of key market players - Multi cancer early detection market

Companies Mentioned

  • Illumina, Inc.
  • GRAIL, Inc.
  • Exact Sciences Corporation
  • FOUNDATION MEDICINE, INC.
  • AnchorDx
  • Guardant Health
  • Burning Rock Biotech Limited
  • GENECAST
  • Beijing Lyman Juntai International Medical Technology Development Co.
  • Freenome Holdings, Inc
  • Elypta AB

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages125
PublishedDecember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.12 billion
Forecasted Market Value ( USD ) by 2030 $ 2.86 billion
Compound Annual Growth Rate17.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Multi Cancer Early Detection Global Market Report 2024 - Product Image

Multi Cancer Early Detection Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Multi-cancer Early Detection Market 2025-2029 - Product Image

Multi-cancer Early Detection Market 2025-2029

  • Report
  • 202 Pages
  • Global
From
Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Assay Kits And Reagents), By Test (Blood Test, Imaging Test), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Blood Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Assay Kits And Reagents), By Test (Blood Test, Imaging Test), By End Use (Hospitals & Clinics), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Asia Pacific Multi Cancer Early Detection Market Size, Share & Trends Analysis Report By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Asia Pacific Multi Cancer Early Detection Market Size, Share & Trends Analysis Report By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 102 Pages
  • Asia Pacific
From
Multicancer Screening Market by Product, Test Type, Technology, Cancer Type, End User - Global Forecast 2025-2030 - Product Image

Multicancer Screening Market by Product, Test Type, Technology, Cancer Type, End User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From

About the Multi Cancer Early Detection Market

The Multi Cancer Early Detection market is a subset of the Diagnostics industry that focuses on the early detection of multiple types of cancer. This market is driven by the need to detect cancer at its earliest stages, when it is most treatable. Diagnostic tests used in this market include blood tests, imaging tests, and biopsies. These tests are used to detect cancer markers, such as proteins, hormones, and genetic mutations. The Multi Cancer Early Detection market is highly competitive, with many companies offering innovative products and services. Companies in this market include Grail, Freenome, Guardant Health, and Tempus. These companies are focused on developing tests that can detect multiple types of cancer with high accuracy and sensitivity. Additionally, these companies are working to make their tests more accessible and affordable for patients. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.